Drug · CHEMBL11359
CISPLATIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CISPLATIN. Drugs and targets, record CHEMBL11359. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL11359
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
(sp-4-2)-diamminedichloroplatinum, CIS-DDP, CISPLATIN COMPONENT OF INT-230-6, CISPLATIN COMPONENT OF INT230-6, Cis-diamminedichloroplatinum, Cis-diamminedichloroplatinum ii, Cis-diamminedichloroplatinum(ii), Cis-platin, Cis-platinum ii, Cisplatine, Cisplatino, Cisplatinum, Fauldiscipla, Liplacis, NSC-119875, Peyrone's salt
- ChEMBL
- Open Targets' highest stage
- Approval, for 2 of its 296 diseases, from ATC and ClinicalTrials.gov
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases296
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| non-small cell lung carcinoma | Phase 3 | ClinicalTrials.gov | 544 | 543 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| head and neck squamous cell carcinoma | Phase 3 | ClinicalTrials.gov | 242 | 242 | https://conductscience.org/library/drugs?q=MONDO_0010150 |
| nasopharyngeal carcinoma | Phase 3 | ClinicalTrials.gov | 210 | 210 | https://conductscience.org/library/drugs?q=MONDO_0015459 |
| cervical cancer | Phase 3 | ClinicalTrials.gov | 178 | 178 | https://conductscience.org/library/drugs?q=MONDO_0002974 |
| gastric cancer | Phase 3 | ClinicalTrials.gov | 148 | 148 | https://conductscience.org/library/drugs?q=MONDO_0001056 |
| small cell lung carcinoma | Phase 3 | ClinicalTrials.gov | 144 | 144 | https://conductscience.org/library/drugs?q=MONDO_0008433 |
| esophageal squamous cell carcinoma | Phase 3 | ClinicalTrials.gov | 134 | 134 | https://conductscience.org/library/drugs?q=MONDO_0005580 |
| breast cancer | Phase 3 | ClinicalTrials.gov | 103 | 103 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| esophageal cancer | Phase 3 | ClinicalTrials.gov | 95 | 95 | https://conductscience.org/library/drugs?q=MONDO_0007576 |
| biliary tract cancer | Phase 3 | ClinicalTrials.gov | 74 | 74 | https://conductscience.org/library/drugs?q=MONDO_0003060 |
1 to 10 of 296Source Open Targets
See all 296 diseasesTrials3,441
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 6 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 21 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00148798 | Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) | Phase 3 | 1,861 | 2011-10-04 | cisplatin | Its name | ClinicalTrials.gov |
| NCT00025259 | Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease | Phase 3 | 1,734 | 2017-03-07 | cisplatin | Its name | ClinicalTrials.gov |
| NCT03675737 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | Phase 3 | 1,579 | 2023-10-12 | cisplatin | Its name | ClinicalTrials.gov |
| NCT00951496 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Phase 3 | 1,560 | 2018-05-18 | cisplatin | Its name | ClinicalTrials.gov |
| NCT00324805 | Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery | Phase 3 | 1,501 | 2018-02-14 | cisplatin | Its name | ClinicalTrials.gov |
| NCT00063999 | Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | Phase 3 | 1,381 | 2018-04-23 | cisplatin | Its name | ClinicalTrials.gov |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | Phase 3 | 1,351 | 2016-07-18 | cisplatin | Its name | ClinicalTrials.gov |
| NCT00134030 | Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma | Phase 3 | 1,334 | 2023-06-07 | cisplatin | Its name | ClinicalTrials.gov |
| NCT03036098 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer | Phase 3 | 1,314 | 2025-09-18 | cisplatin | Its name | ClinicalTrials.gov |
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | Phase 3 | 1,214 | 2023-01-04 | cisplatin | Its name | ClinicalTrials.gov |
1 to 10 of 3,441
See all 3,441 trialsComparisons in its trials518
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE) | 267 of 785 | 206 of 787 | 1,572 | NCT03675737 | Trial comparisons |
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Experienced an Adverse Event (AE) | 776 of 785 | 771 of 787 | 1,572 | NCT03675737 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Bevacizumab): serious adverse events | 424 of 738 | 563 of 735 | 1,473 | NCT00324805 | Trial comparisons |
| Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): deaths from any cause | 271 of 647 | 280 of 665 | 1,312 | NCT00063999 | Trial comparisons |
| Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): serious adverse events | 217 of 647 | 156 of 665 | 1,312 | NCT00063999 | Trial comparisons |
| 10 MG/KG IPILIMUMAB + PLATINUM/ETOPOSIDE vs PLACEBO + PLATINUM/ETOPOSIDE: serious adverse events | 316 of 562 | 278 of 561 | 1,123 | NCT01450761 | Trial comparisons |
| Cetuximab Plus Chemotherapy vs Chemotherapy Alone: Safety - Number of Patients Experiencing Any Adverse Event | 545 of 548 | 549 of 562 | 1,110 | NCT00148798 | Trial comparisons |
| Cetuximab Plus Chemotherapy vs Chemotherapy Alone: serious adverse events | 325 of 548 | 244 of 562 | 1,110 | NCT00148798 | Trial comparisons |
| Necitumumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: deaths from any cause | 476 of 538 | 487 of 541 | 1,079 | NCT00981058 | Trial comparisons |
| Necitumumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: serious adverse events | 262 of 538 | 208 of 541 | 1,079 | NCT00981058 | Trial comparisons |
1 to 10 of 518
See all 518 comparisons in its trialsPapers from its trials2,035
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials9
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Symbol Scan Task | 2 | 0 | ConductCognition |
| Verbal Learning | 2 | 0 | ConductCognition |
| Arithmetic Fluency Task | 1 | 0 | ConductCognition |
| Block Copy Test | 1 | 0 | ConductCognition |
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Digit Span Test | 1 | 0 | ConductCognition |
| Hidden Path Learning | 1 | 0 | ConductCognition |
| 1-Back Task | 1 | 0 | ConductCognition |
| Paired Associate Learning | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL11359
GET https://conductscience.org/api/drugs/v1/CHEMBL11359/diseases?page=2